Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16
Medivir AB (NASDAQ Stockholm: MVIR) is set to present mature clinical data for its fostrox (fostroxacitabine) and Lenvima® (lenvatinib) combination therapy at the ESMO Congress in Barcelona on September 16, 2024. The presentation will focus on results from a phase 1b/2a study treating advanced hepatocellular carcinoma (HCC) that progressed after immunotherapy. Dr. Hong Jae Chon from CHA Bundang Medical Center in Korea will present the abstract.
Following the presentation, Medivir will host a webcast at 13:45 CET, featuring Dr. Chon and Dr. Pia Baumann, Medivir's CMO, to discuss the data and answer questions. Dr. Chon will also provide context by comparing the results to current second-line clinical practices for liver cancer treatment.
Medivir AB (NASDAQ Stockholm: MVIR) presenterà dati clinici maturi per la sua terapia combinata di fostrox (fostroxacitabina) e Lenvima® (lenvatinib) al Congresso ESMO a Barcellona il 16 settembre 2024. La presentazione si concentrerà sui risultati di uno studio di fase 1b/2a per il trattamento del carcinoma epatocellulare avanzato (HCC) che ha mostrato progressione dopo la immunoterapia. Il Dr. Hong Jae Chon del CHA Bundang Medical Center in Corea presenterà l'abstract.
Dopo la presentazione, Medivir ospiterà un webcast alle 13:45 CET, con la partecipazione del Dr. Chon e della Dr.ssa Pia Baumann, CMO di Medivir, per discutere i dati e rispondere alle domande. Il Dr. Chon fornirà anche un contesto confrontando i risultati con le attuali pratiche cliniche di seconda linea per il trattamento del cancro al fegato.
Medivir AB (NASDAQ Estocolmo: MVIR) está programado para presentar datos clínicos madurados para su terapia de combinación de fostrox (fostroxacitabina) y Lenvima® (lenvatinib) en el Congreso ESMO en Barcelona el 16 de septiembre de 2024. La presentación se centrará en los resultados de un estudio de fase 1b/2a que trata el carcinoma hepatocelular avanzado (HCC) que progresó tras la inmunoterapia. El Dr. Hong Jae Chon del CHA Bundang Medical Center en Corea presentará el resumen.
Tras la presentación, Medivir organizará un webcast a las 13:45 CET, con la participación del Dr. Chon y la Dra. Pia Baumann, CMO de Medivir, para discutir los datos y responder preguntas. El Dr. Chon también proporcionará contexto comparando los resultados con las prácticas clínicas actuales de segunda línea para el tratamiento del cáncer de hígado.
Medivir AB (NASDAQ 스톡홀름: MVIR)는 2024년 9월 16일 바르셀로나에서 열리는 ESMO 회의에서 소프록스(포스트록사키타빈)와 렌비마®(렌바티닙) 병합 치료에 대한 성숙한 임상 데이터를 발표할 예정입니다. 이번 발표는 면역 치료 후 진행된 진행성 간세포암(HCC)을 치료하는 1b/2a 단계 연구의 결과에 중점을 둘 것입니다. 한국의 CHA 분당 의료원 홍재촌 박사가 초록을 발표합니다.
발표 후, Medivir는 13:45 CET에 웨비나를 개최하여 홍 박사와 Medivir의 CMO인 피아 바우만 박사가 데이터를 논의하고 질문에 답변합니다. 홍 박사는 또한 현재 간암 치료를 위한 2차 임상 관행과 결과를 비교하여 맥락을 제공할 것입니다.
Medivir AB (NASDAQ Stockholm: MVIR) se prépare à présenter des données cliniques matures pour sa thérapie combinée de fostrox (fostroxacitabine) et Lenvima® (lenvatinib) lors du Congrès ESMO à Barcelone le 16 septembre 2024. La présentation se concentrera sur les résultats d'une étude de phase 1b/2a traitant le carcinome hépatocellulaire avancé (CHC) qui a progressé après une immunothérapie. Le Dr. Hong Jae Chon du CHA Bundang Medical Center en Corée présentera le résumé.
Après la présentation, Medivir organisera un webcast à 13h45 CET, avec la participation du Dr. Chon et du Dr. Pia Baumann, CMO de Medivir, pour discuter des données et répondre aux questions. Le Dr. Chon fournira également un contexte en comparant les résultats aux pratiques cliniques de seconde ligne actuelles pour le traitement du cancer du foie.
Medivir AB (NASDAQ Stockholm: MVIR) wird am ESMO-Kongress in Barcelona am 16. September 2024 ausgereifte klinische Daten zu seiner Fostrox (Fostroxacitabine) und Lenvima® (Lenvatinib) Kombinationsbehandlung präsentieren. Der Schwerpunkt der Präsentation liegt auf den Ergebnissen einer Phase 1b/2a-Studie, die fortgeschrittenes hepatozelluläres Karzinom (HCC) behandelt, das nach einer Immuntherapie fortgeschritten ist. Dr. Hong Jae Chon vom CHA Bundang Medical Center in Korea wird das Abstract präsentieren.
Nach der Präsentation wird Medivir um 13:45 CET einen Webcast veranstalten, an dem Dr. Chon und Dr. Pia Baumann, CMO von Medivir, teilnehmen werden, um die Daten zu diskutieren und Fragen zu beantworten. Dr. Chon wird auch den Kontext bereitstellen, indem er die Ergebnisse mit den aktuellen klinischen Zweitlinienpraktiken für die Behandlung von Leberkrebs vergleicht.
- Presentation of mature clinical data for fostrox + Lenvima combination therapy at ESMO Congress
- Phase 1b/2a study results for advanced HCC treatment to be revealed
- Webcast scheduled to discuss data and answer questions, indicating transparency
- Comparison with current second-line clinical practices to be provided, offering context for the results
- None.
The abstract, titled "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations. Results from a multi-center phase 1b/2a study." will be presented by Dr Hong Jae Chon, CHA Bundang Medical Center in
After the presentation Medivir will also host a webcast where Dr Chon and Dr Pia Baumann, Chief Medical Officer at Medivir, will present the data and answer questions. The webcast will take place on September 16, at 13.45 CET, and will be streamed via a link on the website: www.medivir.com/investors/presentations.
In addition to the presentation of phase 1b/2a data, Dr Chon with his experience of treating liver cancer patients, will provide additional context to the data by comparing with what can be expected with current clinical practice in second-line.
The poster and the presentation from the webcast will be available on Medivir's website after the webcast.
For additional information, please contact:
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About fostrox
Fostrox is a liver-targeted inhibitor of DNA replication that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling an active chemotherapy (troxacitabine) with a prodrug tail. This design enables fostrox to be administered orally and travel directly to the liver where the active substance is released locally in the liver. With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with various types of liver cancer. A phase 1b monotherapy study with fostrox has been completed and a phase 1b/2a combination study in HCC is ongoing where it has shown encouraging anti-cancer efficacy with a good safety and tolerability profile.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver and it is the fastest growing cancer in the
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
1) Rumgay et al.,European Journal of Cancer 2022 vol.161, 108-118.
2) Yang, J.D.,
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivir-to-present-mature-clinical-data-for-fostrox--lenvima-at-esmo-conference-and-to-host-a-webcast-on-september-16-302246468.html
SOURCE Medivir
FAQ
What will Medivir present at the ESMO Congress on September 16, 2024?
Who will present Medivir's (MVIR) clinical data at the ESMO Congress?
When and where will Medivir (MVIR) host a webcast to discuss the ESMO Congress presentation?
What additional context will be provided during Medivir's (MVIR) webcast on September 16, 2024?
